ArticleNature communications2026
Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Immunity to Streptococcus pyogenes infection appears to develop progressively through repeated exposure during early life. However, the intensity or duration of exposure required is unknown, as to why some individuals appear to develop immunity, despite having few or no previously detected infections. Here, drawing on samples from a human model of pharyngeal S. pyogenes infection, we investigate whether symptomatic disease is required for induction of protective immune responses. We show that challenge with M75 S. pyogenes elicits M75-specific serum antibodies and memory B cells in both symptomatic and asymptomatic participants, with responses persisting for at least 6 months. M75-specific IgG from asymptomatic participants exhibit altered Fc glycosylation traits post-challenge, associated with enhanced binding to M75 S. pyogenes and protection when transferred into a murine model of respiratory tract infection. These findings demonstrate that asymptomatic exposure to M75 S. pyogenes contributes to the development of streptococcal immunity that emerges by adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.